Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Intangibles (2023 - 2025)

Rein Therapeutics filings provide 3 years of Intangibles readings, the most recent being $13.5 million for Q4 2025.

  • For the quarter ending Q4 2025, Intangibles fell 68.01% year-over-year to $13.5 million, compared with a TTM value of $13.5 million through Dec 2025, down 68.01%, and an annual FY2025 reading of $13.5 million, down 68.01% over the prior year.
  • Intangibles hit $13.5 million in Q4 2025 for Rein Therapeutics, down from $42.2 million in the prior quarter.
  • The five-year high for Intangibles was $79.2 million in Q4 2023, with the low at $13.5 million in Q4 2025.
  • Median Intangibles over the past 3 years was $42.2 million (2024), compared with a mean of $55.5 million.
  • The sharpest move saw Intangibles plummeted 46.72% in 2024, then plummeted 68.01% in 2025.
  • Year by year, Intangibles stood at $79.2 million in 2023, then crashed by 46.72% to $42.2 million in 2024, then plummeted by 68.01% to $13.5 million in 2025.
  • According to Business Quant data, Intangibles over the past three periods came in at $13.5 million, $42.2 million, and $42.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.